DDInter847 DDInter1376
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Guanfacine {u} (Compound) resembles {v} (Compound) Phenacemide
Guanfacine {u} (Compound) treats {v} (Disease) hypertension
Guanfacine {u} (Compound) binds {v} (Gene) NISCH
Guanfacine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Guanfacine {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic alpha2-Agonists
Guanfacine {u} (Compound) causes {v} (Side Effect) Dyspepsia
Guanfacine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Guanfacine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Guanfacine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Guanfacine {u} may lead to a major life threatening interaction when taken with {v} Imatinib
Guanfacine (Compound) resembles Phenacemide (Compound)
Guanfacine (Compound) treats hypertension (Disease)
Guanfacine (Compound) binds NISCH (Gene)
Guanfacine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Guanfacine (Compound) is included by Adrenergic alpha2-Agonists (Pharmacologic Class)
Guanfacine (Compound) causes Dyspepsia (Side Effect)
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Guanfacine may lead to a major life threatening interaction when taken with Crizotinib
Guanfacine may lead to a major life threatening interaction when taken with Imatinib